Association between β2-adrenoceptor (ADRB2) haplotypes and insulin resistance in PCOS

Mariana L. Tellechea*,†,1, Damián O. Muzzio*,1, Andrea E. Iglesias Molli*, Susana H. Belli‡, Mabel N. Graffigna‡, Oscar A. Levalle‡, Gustavo D. Frechtel*§ and Gloria E. Cerrone*

*Genetics and Molecular Biology, Department of Microbiology, Immunology and Biotechnology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), †Humoral Immunity Institute ‘Prof. Ricardo A. Margn’ (IDEHU), National Research Council (CONICET), School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), ‡Endocrine Division, Hospital Carlos Durand, and §Diabetes Genetics Section of the Division of Genetics, Clinical Hospital ‘José de San Martín’, University of Buenos Aires (UBA), Buenos Aires, Argentina

Summary

Objective The aim of this study was to explore β2-adrenoceptor (ADRB2) haplotype associations with phenotypes and quantitative traits related to insulin resistance (IR) and the metabolic syndrome (MS) in a polycystic ovary syndrome (PCOS) population. A secondary purpose was to assess the association between ADRB2 haplotype and PCOS.

Design Genetic polymorphism analysis. Cross-sectional case–control association study.

Setting Medical University Hospital and research laboratory.

Patients One hundred and sixty-five unrelated women with PCOS and 116 unrelated women without PCOS (control sample).

Measurements Clinical and biochemical measurements, and ADRB2 genotyping in PCOS patients and control subjects.

Methods ADRB2 haplotypes (comprising rs1042711, rs1801704, rs1042713 and rs1042714 in that order), genotyping and statistical analysis to evaluate associations with continuous variables and traits related to IR and MS in a PCOS population. Associations between ADRB2 haplotypes and PCOS were also assessed.

Results We observed an age-adjusted association between ADRB2 haplotype CCGG and lower insulin (P = 0.018) and HOMA (P = 0.008) in the PCOS sample. Interestingly, the expected differences in surrogate measures of IR between cases and controls were not significant in CCGG/CCGG carriers. In the case–control study, genotype CCGG/CCGG was associated with a 14% decrease in PCOS risk (P = 0.043), taking into account confounding variables.

Conclusions Haplotype I (CCGG) has a protective role for IR and MS in PCOS.

(Received 8 May 2012; returned for revision 23 May 2012; finally revised 17 July 2012; accepted 14 August 2012)

Introduction

Polycystic ovary syndrome (PCOS) is recognized as the most common endocrine disorder in women of reproductive age.1–3 Insulin resistance in these patients may play an important role in the development of the syndrome where insulin has an influence on LH and steroidogenesis. Besides, many PCOS women are obese and develop a number of complications associated with obesity. Genetic variants that influence insulin response and/or obesity may be related to increased prevalence of PCOS.

The pathophysiological mechanisms responsible for the development of obesity and insulin resistance (IR) in PCOS are multifactorial, and abnormal regulation of adipocyte lipolysis might be a key component. Obesity is associated with an increase in basal lipolysis4 but a decrease in catecholamine-stimulated lipolysis5,6 where the beta-adrenergic receptor plays a major role.4 In PCOS, catecholamine-induced lipolysis is reduced in subcutaneous (sc) fat7 but increased in visceral fat,8 resulting in an increase in lipid content in fat cells and excess of fatty acid delivery to the liver, which could lead to hyperinsulinaemia, glucose intolerance and dyslipidaemia.9,10 Such lipolysis defects are identical to those observed in the metabolic syndrome (MS), so it could be a primary pathogenic mechanism for the development of the three disorders: obesity, PCOS and MS.

Insulin resistance and concomitant hyperinsulinaemia are common features in PCOS patients (50–70%)11 and, together with obesity,12 are frequent pathogenetic factors in MS. Moreover, MS frequency is increased in PCOS women compared with age- and weight-matched controls13,14 with an overall prevalence of 43–47%,15 especially in women with high insulin levels and BMI.16

Correspondence: Gloria E. Cerrone, Genetics and Molecular Biology, Department of Microbiology, Immunology and Biotechnology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), Avda Córdoba 2351, 4to piso, sala 5, Buenos Aires (1120), Argentina. Tel.: 5411 5950-8780; E-mail: gcerrone@ffyb.uba.ar

*Genetics and Molecular Biology, Department of Microbiology, Immunology and Biotechnology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), Avda Córdoba 2351, 4to piso, sala 5, Buenos Aires (1120), Argentina.

†Mariana L. Tellechea and Damián O. Muzzio have contributed equally to this work.
An obesogenic lifestyle seems to be the main factor underpinning common variants of obesity and insulin resistance; however, the role of genetic predisposition in various conditions, including PCOS, is increasingly recognized.\textsuperscript{17,18}

We studied the $\beta_2$-adrenoceptor (ADRB2) owing to its dominant effect as lipolytic receptor in human white adipose tissue\textsuperscript{19} and skeletal muscle.\textsuperscript{20} Recently, Masuo\textsuperscript{21} reviewed the close relationships between $\beta_2$- and $\beta_3$-adrenoceptor polymorphisms accompanying elevated sympathetic nervous activity, blood pressure elevation, weight gain and insulin resistance.

The aim of this study was to explore associations between ADRB2 haplotypes and phenotypes and quantitative metabolic traits related to obesity, lipid metabolism and IR in a PCOS population. A secondary purpose of the present study was to perform a cross-sectional case–control association study between PCOS and ADRB2 haplotypes.

**Subjects and methods**

**Subjects**

A total of 220 women with PCOS were recruited from outpatients attending the Endocrine Division of Hospital Durand, Buenos Aires (2006–2010). A sample of 165 unrelated women was selected for the molecular study according to the availability of metabolic and anthropometric parameters, informed consent and the absence of consanguinity.

Polycystic ovary syndrome was defined by (i) the presence of hyperandrogenaemia or clinical hyperandrogenism, (ii) oligo-ovulation, and (iii) the exclusion of other disorders, as described by the NIH 1990 criteria.\textsuperscript{22}

Patients who had any of the following illnesses, conditions or requirement were excluded: Cushing’s syndrome, 21-hydroxylase deficiency, thyroid dysfunction, hepatic or haematological disease, diabetes or hyperprolactinaemia.

Controls were unrelated healthy women, without clinical components of PCOS or family history of PCOS (self-reported), with normal weight, waist circumference <88 cm, normal findings on medical examination and blood count, and not taking any medication. Volunteers were Argentinian of self-reported European ancestry, particularly from southern European countries (Spain and Italy), living in Buenos Aires metropolitan area, randomly recruited between April 2007 and April 2009.

This work was carried out in accordance with the Declaration of Helsinki and approved by the hospital ethics committee. All subjects gave their written consent.

**Clinical measurements**

Anthropometric measurements (height, weight and waist circumference) were determined by a standardized protocol in every subject. Waist circumference (WC) was measured to the nearest 0.1 cm, with an inelastic fibreglass standard tape, in a horizontal plane, over the unclothed abdomen, at the narrowest point between the costal margin and iliac crest. Measurement was made at the end of a normal expiration. Systolic (SBP) and diastolic (DBP) blood pressures were recorded using a standard mercury sphygmomanometer after at least 10 min of rest.

Blood samples were drawn after a 12-h overnight fast. Total cholesterol (T-C), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) were determined in serum by enzymatic methods using commercial kits (TG Triglycerides GPO-PAP, CHOL Cholesterol CHOD-PAP and Phosphotungstate Precipitant, Roche Diagnostics, Mannheim, Germany) in a Hitachi 727 autoanalyzer. Intra-assay coefficients of variation (CVs) for TG and T-C were 1.3–1.1%, respectively. Interassay CVs were 2.4% and 1.5%, respectively. Fasting plasma glucose (FPG) was determined by a glucose-oxidase method (GLU Glucose GOD-PAP, Roche Diagnostics). Intra- and interassay CVs were 0.9 and 1.8%, respectively. Fasting serum insulin (FI) was measured by radioimmunnoassay (RIA) with a commercial kit (Human Insulin-specific RIA kit, Linco Research Inc., St. Louis, MO, USA) using a gamma counter (DPC Gambyt CR, Los Angeles, USA), with a lower detection limit of 2 mU/l, intra- and interassay CVs being <1 and 7.43%, respectively, and cross-reactivity <0.2% for intact human proinsulin. Homeostasis Model Assessment (HOMA) was calculated with the following formula: basal glucose mm × basal insulin mIU/l/22.5.

**Phenotype assessment**

In Table 1, we showed significant differences in continuous variables between PCOS and control samples (BMI, WC, SBP, DBP, FG, TC, TG, HDL-C, TG/C-HDL, fasting insulin).

Each subject was assessed for the presence of (i) MS using the AHA/NHLBI (American Heart Association/National Heart, Lung and Blood Institute) criteria\textsuperscript{23} [any three or more of the following: WC ≥ 88 cm, fasting TG ≥ 1.7 mm, SBP ≥ 130 mmHg, Table 1. Clinical characteristics

| Measure            | Control women | Polycystic ovary syndrome women | $P$  | $P^a$ |
|--------------------|---------------|-------------------------------|------|-------|
| n                  | 121           | 165                           |      |       |
| Age                | 30-78 ± 0.78  | 26-42 ± 0.50                 | <0.001| NA    |
| BMI (kg/m$^2$)     | 21-08 ± 0.18  | 29-28 ± 0.63                 | <0.001| <0.001|
| WC (cm)            | 71-05 ± 0.68  | 89-32 ± 1.61                 | <0.001| <0.001|
| SBP (mmHg)         | 109-73 ± 2.33 | 111-23 ± 1.78                | NS   | NS    |
| DBP (mmHg)         | 72-75 ± 0.91  | 72-22 ± 1.38                 | NS   | NS    |
| FG (mm)            | 4-50 ± 0.04   | 5-07 ± 0.15                  | <0.001| <0.001|
| TC (mm)            | 4-25 ± 0.08   | 4-88 ± 0.09                  | <0.001| <0.001|
| TG (mm)            | 0-76 ± 0.03   | 1-40 ± 0.08                  | <0.001| <0.001|
| HDL-C (mm)         | 1-47 ± 0.04   | 1-33 ± 0.04                  | 0-010| 0-025 |
| TG/HDL-C           | 1-22 ± 0.06   | 2-80 ± 0.24                  | <0.001| <0.001|
| Fasting Insulin (mIU/l) | 5-65 ± 0.27  | 14-27 ± 0.86                | <0.001| <0.001|
| HOMA               | 1-09 ± 0.05   | 3-23 ± 0.22                  | <0.001| <0.001|

$n$, number of subjects; NA, not applicable; NS, not significant; $P^a$, age adjusted $P$ value.

Values are expressed as mean ± typical error of mean.
and/or DBP ≥ 85 mmHg, fasting HDL-C ≤ 1.03 mmol and FPG ≥ 5.6 mmol; (ii) obesity (BMI ≥ 30.0 kg/m²), (iii) abdominal obesity (waist circumference ≥ 88 cm), (iv) hypertriglyceridaemia (HTG) fasting TG ≥ 1.7 mmol, (v) hypertriglyceridaemic waist (HTGW) (TG ≥ 1.7 mmol + WC ≥ 88 cm), (vi) decreased HDL-C (fasting HDL-C < 1.03 mmol), (vii) impaired fasting glucose (IFG = Fasting plasma glucose ≥ 5.6 mmol), (viii) IR (insulin resistance) estimated by 75th percentile HOMA cut-off point (HOMA > 2.3 = IR).

Genotyping

As described previously, we developed a simple method of genotyping ADBR2 haplotypes composed of rs1042711, rs1042714 and rs1042713. The rs1042711 (−47 C/T) and rs1042714 (−20 C/T) are located in the 5’ leader cistron and rs1042713 (c.46A>G, Arg16Gly, R16E) and rs1042714 (c.79C>G, Gln27Glu, Q27E) in exon 1. It was possible to identify three major haplotypes (I, II and III) considering the different combinations of the four polymorphisms presented in the amplified fragment.

Data from International Haplotype Map Project (http://hapmap.ncbi.nlm.nih.gov/) for European Americans from Utah (HapMap-CEU) and the software Haploview 4.1 provided us tag-SNPs in LD, with a minor allele frequency (MAF) ≥ 0.10, minimum $r^2$ ≥ 0.8 and minimum LOD ≥ 3.0.

Briefly, genomic DNA was isolated from peripheral blood according to standard procedures. PCR was carried out to amplify a 353-bp region of ADBR2, and single-strand conformation polymorphisms (SSCP) gel electrophoresis was performed and visualized with silver staining. The PCR–SSCP procedure was validated with automated sequencing.

Genotyping accuracy was assessed by inclusion of duplicates and controls.

Statistical analysis

Analyses were performed separately for haplotypes and followed up by analysis of individual SNPs. Quantitative data were expressed as means ± SE. For comparison of continuous variables, we conducted one-way ANOVA with Levine’s Test for equality of variances. Otherwise, we used Welch test. Regression analyses were used to adjust for possible confounding variables (age, BMI).

The effects of a particular haplotype load (0 = no copies, 1 = 1 copy and 2 = 2 copies of the particular haplotype) on continuous or categorical variables were tested using linear or logistic regression, respectively.

Deviation of the genotype distribution from the Hardy–Weinberg Equilibrium (HWE) was tested using Chi square test for each SNP, for both samples.

For individual SNP association analyses, we performed 1-df (1 degrees of freedom) test of association (dominant and recessive genetic models were tested).

Differences between prevalence rates were assessed by Fisher’s exact test.

We calculated odds ratio (OR) and 95% confidence intervals (95%CI) when appropriate.

A P-value <0.05 was considered statistically significant. Statistical analyses were conducted using the program for Statistical Package for the Social Sciences, version 13.0 for Windows (SPSS, Inc., Chicago, IL, USA).

Results

The prevalence of MS and related traits in PCOS was as follows: MS (using AHA/NHLBI criteria) 20.2%; Obesity 42.1%; abdominal obesity 52.8%; HTG 25.0%; HTGW 19.6%; decreased HDL-C 21.9%; IFG 11.5%. Simultaneously, the prevalence of IR defined by HOMA for lean and obese PCO patients, respectively (34% and 70%), was determined. In Table 1, we showed the significant differences in continuous variables observed between PCOS and control samples (BMI, WC, SBP, DBP, FG, TC, TG, HDL-C, TG/C-HDL, fasting insulin).

We identified the three main haplotypes that we previously observed in another Argentinian sample, which correlated with the haplotypes first described by Drysdale et al. The frequencies of the three haplotypes (rs1042711, rs1801704, rs1042713 and rs1042714 in that order) were CCGG (I) 0.31; TTAC (II) 0.38 and TTGC (III) 0.31.

We identified the six genotypes CCGG/CCGG (I/I), CCGG/TTAC (I/II), CCGG/TTGC (I/III), TTAC/TTAC (II/II), TTAC/TTGC (II/III) and TTGC/TTGC (III/III).

ADRB2 haplotype frequency distributions according to phenotypes related to MS in PCOS

We compared the overall frequency differences (3 × 2 contingency table) across the three possible haplotypes and the different phenotypes, and observed a borderline association between haplotype I (CCGG) and MS ($P = 0.051; OR = 0.41; 95% CI, 0.17–1.01$). We could not find any significant association with obesity, abdominal obesity, IFG, HTG, decreased HDL-C, HTGW or IR phenotypes.

To further explore the effect of the haplotype I load (0 = no copies, 1 = 1 copy and 2 = 2 copies of the particular haplotype), we performed logistic regression analysis. We found a statistically significant association between haplotype I and MS ($P = 0.042; OR = 0.37; 95% CI, 0.14–0.97$), but differences were no longer significant after taking into account age ($P = 0.077$). No other significant associations were found between haplotype load and phenotypes under study in the PCOS sample.

Haplotype I was less represented in the PCOS IR-subgroup (HOMA > 2.3) (haplotype I frequencies in IR and non-IR women were 0.27 and 0.37, respectively), and we observed an association with insulin resistance taking into account age ($P = 0.083$ and adjusted-$P = 0.033$). Although haplotype I was less represented in the PCOS obese subgroup (haplotype I frequency in obese and nonobese individuals was 0.18 and 0.35, respectively), we did not observe any association with obesity ($P = 0.086$ and $P = 0.229$ when age adjusted).
Haplotype load – association analysis of quantitative metabolic traits in PCOS

The effects of haplotype I load on quantitative metabolic traits are represented in Figure 2. In PCOS, the correlation between decreased values of BMI, insulin, HOMA, TG/HDL-C, WC and BMI, and increase in haplotype I (X/X, I/X and I/I) load are shown.

We performed linear regression analysis to assess the effects of a particular haplotype load on quantitative metabolic traits. We found an association of haplotype I load (CCGG) with BMI ($P = 0.040$), insulin ($P = 0.015$) and HOMA ($P = 0.017$). Differences in insulin and HOMA remained significant, taking into account age ($P = 0.018$ and $P = 0.008$, respectively) and after adjusting for age and BMI ($P = 0.032$ and $P = 0.014$, respectively).

We did not find any other significant regression association between haplotype I and lipid and/or other obesity-related variables in PCOS patients (waist circumference, triglycerides and TG/HDL-c). Data not shown.

No significant association of haplotypes II (TTAC) or III (TTGC) with continuous variables was apparent.

Case-control association study between ADRB2 haplotypes and PCOS

We did not find any evidence of association when comparing overall frequency differences across the three possible haplotypes between cases (PCOS) and controls ($P = 0.084$, Fig. 1).

We performed logistic regression analysis to assess the association between haplotype I load and presence of PCOS. We included in the model the variables previously associated with haplotype I in the PCOS sample (fasting insulin, HOMA-IR and MS) and age. Association of haplotype I with PCOS was significant under a recessive model (I/I vs I/X + X/X) ($P = 0.043$; OR = 0.14; 95% CI, 0.02 – 0.93).

The same study was performed with noninsulin-resistant PCOS (HOMA < 2.3 by 75th percentile HOMA value) compared to the control group (noninsulin-resistant), and we observed a significant association of haplotype I with PCOS under a recessive model (I/I vs I/X + X/X) ($P = 0.004$; OR = 0.026; 95% CI, 0.002 – 0.32).

Taking into consideration the intra PCOS association study performed previously, we analysed the contribution of haplotype I load to quantitative traits related to obesity, lipid metabolism and surrogate measures of IR, between cases (PCOS) and controls. Figure 2 shows that the PCOS genotype X/X carriers’ subgroup (without haplotype I) had significantly higher surrogate measures of IR (insulin, HOMA, TG and TG/HDL-C ratio) than controls ($P < 0.005$ adjusted by age and BMI). The genotype I/X individuals showed the same results, but, interestingly, in the I/I genotype carriers’ subgroup, differences between cases and controls were not significant. The same results were observed when analysis was performed between non-IR PCOS and nonobese PCOS vs controls (non-IR and nonobese, respectively), data not shown.

WC and BMI were compared, and statistically significant differences were observed between cases and controls, independently of haplotype I presence ($P < 0.005$ adjusted by age and BMI, Fig. 2).

Single-locus analysis

We only performed single-locus analysis of rs1042713 and rs1042714. rs1042711 in our sample seemed to be linked to rs1801704 and rs1042714 as we only found three haplotypes (CCGG, TTAC and TTGC, I, II and III, respectively). Also, considering the linkage disequilibrium (LD) analysis with HapMap-CEU data, we observed that rs1042714 was in linkage disequilibrium (LD) with rs1801704 ($r^2 = 0.96$) (Figure 3).

Allelic frequencies were as follows: in the control sample: rs1042713 G 0.59 and A 0.41; rs1042714 C 0.68 and G 0.32 in the PCOS sample: rs1042713 G 0.62 and A 0.38; rs1042714 C 0.69 and G 0.31. Both SNPs were in concordance with HWE as follows: rs1042713: Controls $\chi^2 = 0.04$, $P =$ NS; PCOS $\chi^2 = 0.17$, $P =$ NS; rs1042714: Controls $\chi^2 = 1.17$, $P =$ NS; PCOS $\chi^2 = 0.31$, $P =$ NS.

We did not find significant associations of rs1042713 with categorical or continuous variables in the PCOS sample. rs1042714 was not associated with phenotypes (categorical variables) under study in the PCOS sample but rs1042714 GG carriers showed lower fasting insulin ($P = 0.022$) and HOMA ($P = 0.030$) compared with allele C carriers (recessive model). Differences in insulin and HOMA remained significant after taking into account age ($P = 0.021$ and $P = 0.010$, respectively) and after adjusting for age and BMI ($P = 0.035$ and $P = 0.017$, respectively) in the PCOS sample.

rs1042713 and rs1042714 allele and genotype frequencies did not differ significantly between PCOS cases and control subjects.

Fig. 1 ADRB2 haplotype distribution between cases and controls. Frequencies of the three haplotypes I, II and III composed of rs1042711, rs1801704, rs1042713 and rs1042714 in that order: CCGG (I), TTAC (II) and TTGC (III) between PCOS cases and controls. n, number of subjects.
Discussion

This is the first report that explores ADRB2 haplotypes (rs1042711, rs1801704, rs1042713 and rs1042714) for their association with phenotypes and quantitative metabolic traits related to IR, obesity and lipid metabolism, in a Caucasian PCOS population. Beta-adrenergic receptor activity was recently identified in the molecular ontology genes within the protein network constructed by Mohamed-Hussein and Harun, demonstrating a probable role of the gene in the pathophysiology of PCOS.28

We observed an association between ADRB2 haplotype CCGG (I) and absence of MS (significant) or insulin resistance (borderline) in PCOS women; results were confirmed by haplotype I load logistic regression. Although haplotype I was less represented in the PCOS obese subgroup, we did not observe any association with obesity. Furthermore, no associations with abdominal obesity, IFG, HTG, decreased HDL-C, HTGW or IR phenotypes were found.

In PCOS patients, decreased values of BMI, insulin, HOMA, TG/HDL-c, WC and BMI correlated with increased haplotype I load (X/X, I/X and I/I). Particularly, we observed linear regression association of haplotype I load (CCGG) with lower insulin and HOMA.

A case–control association study between ADRB2 haplotypes and PCOS was also performed, and we observed that CCGG/CCGG carriers had significantly lower risk of developing PCOS, taking into account fasting insulin, HOMA-IR, MS and age. Genotype CCGG/CCGG was associated with a 14% decrease in PCOS risk, taking into account these confounding variables. This may therefore indicate that women who shared one or more of the confounding parameters analysed, like fasting insulin, HOMA-IR, MS and the same age, would have a lower risk of developing PCOS if they carried two copies of CCGG/CCGG.
haplotype CCGG. Interestingly, cases and controls within the CCGG/CCGG-carrier group had no significant differences in surrogate measures of IR (insulin, HOMA and TG/HDL-C ratio).

In our previous study in another Argentine population, we found statistically significant frequency differences for haplotype CCGG/CCGG between obese and normal weight subjects (P: 0.0348; odds ratio: 0.2487; CI 95%, 0.07–0.91), indicating a possible protective role of the haplotype CCGG/CCGG for obesity. In the PCOS sample studied in this work, although haplotype CCGG was less represented in obese PCOS women, no significant differences attributable to the ADRB2 haplotypes were observed for WC and BMI.

Taking all the results together, haplotype CCGG appears to have a protective role for IR, and MS in PCOS, regardless of age. Although the present study provides exploratory results and should be confirmed in a second and independent replication cohort, previous association studies have shown conflicting results regarding ADRB2 haplotypes and different phenotypes, as recently analysed in a meta-analysis.29 Ethnic influences and differences in the degree of the phenotypes among research subjects would explain such discordances.30

The vast majority of association studies which have considered ADRB2 as a candidate gene have analysed one or both of the nonsynonymous coding polymorphisms (rs1042713, Arg16Gly and rs1042714, Gln27Glu) in different diseases. In an attempt to explore the association signal, we performed analysis with individual SNPs. rs1042714 GG (Glu27/Glu27) genotype carriers showed lower fasting insulin and HOMA compared with allele rs1042714C carriers (Gln27/Glu27 or Gln27/Gln27) even after adjusting for age and BMI in the PCOS sample. Kurabayashi et al.31 reported that women with rs1042713AA (not GG, Arg16/Arg16) genotype or with either rs1042714CG (Gln27/Glu27) or GG (Glu27/Glu27) genotype had significantly higher insulin resistance than those with the rs1042713GG (Gly16/Gly16) and rs1042714CC (Gln27/Gln27) genotypes, in a Japanese PCOS sample.

We did not find allelic association with PCOS in the sample studied. In the previous case–control study, conducted by Kurabayashi et al.31 (59 women with PCOS and 97 controls), the rs1042714G allele frequency was shown to be significantly higher in PCOS patients when compared to controls, while the rs1042713G allele frequency was only slightly lower in the PCOS group as compared to controls. In contrast, we observed that the rs1042713 G allele frequency was only slightly higher in the PCOS group as compared to controls (0.62 vs 0.59), and no differences were observed for the rs1042714 G allele (0.32 vs 0.31). Contradictory results are probably due to the different allele frequencies observed (HapMap-JPT/CEU allele distribution, http://hapmap.ncbi.nlm.nih.gov/) or different LD structure in both populations. Furthermore, discrepancies in results have been reviewed by Masuo21 in relation to ADRB2 polymorphisms and obesity, glucose intolerance, hypertension and/or diabetes. It must be considered that SNPs may be acting together in specific haplotype pairs32 although each may have a different modest effect32–35 and might address these inconsistencies.

Of note, a genewide association study (GWAS) of the ADRB2 candidate region, by means of the haplotype-tagging strategy, would require genotyping rs1042713, rs1042714, rs1042718 and rs1042719, to capture 100% of alleles with minor allele frequency ≥ 0.10 (Fig. 3). However, tagging only common SNPs, as we have done, excluded the possibility of discovering any substantial effect associated with low-frequency SNPs.

In conclusion, a protective role of haplotype I in insulin resistance would influence the development of PCOS and other related metabolic disorders such as MS. Considering the complexity and heterogeneity of PCOS,32 and the possible pathogenetic role of the ADRB2 gene, ADRB2 haplotype genotyping in the early stages of PCOS would help to provide a risk predisposition assessment for IR and MS.

Acknowledgement

We declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. This work was supported by the University of Buenos Aires, Argentina (grant numbers B816, 2006–2009; 20120090200856, 2010–2012).

References

1 Asunción, M., Calvo, R.M., San Millán, J.L. et al. (2000) A prosp ective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. The Journal of Clinical Endocrinology and Metabolism, 85, 2434–2438.
2 Franks, S. (2008) Polycystic ovary syndrome in adolescents. International Journal of Obesity (London), 32, 1035–1041.
3 Ehrmann, D.A. (2005) Polycystic ovary syndrome. The New England Journal of Medicine, 352, 1223–1236.
4 Reynisdottir, S., Langin, D., Carlström, K. et al. (1995) Effects of weight reduction on the regulation of lipolysis in adipocytes of women with upper-body obesity. Clinical Science (London), 89, 421–429.
5 Large, V., Reynisdottir, S., Langin, D. et al. (1999) Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. Journal of Lipid Research, 40, 2059–2066.
6 Duncan, R.E., Ahmadian, M., Jaworski, K. et al. (2007) Regulation of Lipolysis in Adipocytes. Annual Review of Nutrition, 27, 79–101.
7 Faulds, G., Rydén, M., Ek, I. et al. (2003) Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism, 88, 2269–2273.
8 Ek, I., Arner, P., Rydén, M. et al. (2002) A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes, 51, 484–492.
9 Wajchenberg, B.L. (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews, 21, 697–738.
10 Bergman, R.N., Van Citters, G.W., Mittelman, S.D. et al. (2001) Central role of the adipocyte in the metabolic syndrome. Journal of Investigative Medicine, 49, 119–126.
11 DeUgarte, C.M., Bartolucci, A.A. & Azziz, R. (2005) Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. *Fertility and Sterility*, 83, 1454–1460.
12 Dunaif, A., Segal, K.R., Futterweit, W. *et al.* (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes*, 38, 1165–1174.
13 Dunaif, A. & Thomas, A. (2001) Current concepts in the polycystic ovary syndrome. *Annual Review of Medicine*, 52, 401–419.
14 Azziz, R. (2007) Evaluation for insulin resistance and comorbidities related to insulin resistance in polycystic ovary syndrome. In: E. Diamanti-Kandarakis, J.E. Nestler, D. Panidis *et al.* (eds) Insulin Resistance and Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment. Humana Press. Totowa, New Jersey, 145–158.
15 Dokras, A., Bochner, M., Hollinrake, E. *et al.* (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. *Obstetrics & Gynecology*, 106, 131–137.
16 Ehrmann, D.A., Liljenquist, D.R., Kasza, K. *et al.* (2006) PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. *Journal of Clinical Endocrinology and Metabolism*, 91, 48–53.
17 Goodarzi, M.O. & Azziz, R. (2006) Diagnosis, epidemiology, and genetics of the polycystic ovarian syndrome. *Best Practice and Research: Clinical Endocrinology and Metabolism*, 20, 193–205.
18 Barber, T.M., Bennett, A.J., Groves, C.J. *et al.* (2008) Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. *Diabetologia*, 51, 1153–1158.
19 Enoksson, S., Talbot, M., Rife, F. *et al.* (2000) Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. *Diabetes*, 49, 2149–2153.
20 Hagstrom-Toft, E., Enoksson, S., Moberg, E. *et al.* (1998) Beta2-Adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo. *American Journal of Physiology*, 275, E909–E916.
21 Masuo, K. (2010) Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome. *International Journal of Hypertension*, 21, 832821.
22 Zawadzki, J.K. & Dunaif, A. (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: A. Dunaif, J.R. Givens, F.P. Haseltine, G.R. Merriam eds. Polycystic Ovary Syndrome. Blackwell Scientific Publications, Boston, 377–384.
23 Grundy, S.M., Cleeman, J.L., Daniels, S.R. *et al.* American Heart Association/National Heart, Lung, and Blood Institute. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, 25, 2735–2752.
24 World Health Organisation. (1997) Obesity: Preventing and Managing the Global Epidemic: Report of the WHO Consultation on Obesity. World Health Organisation, Geneva.
25 Cerrone, G.E., Pérez, M.S., Caputo, M. *et al.* (2007) A simple method for the identification of three major haplotypes of the beta2AR. *Molecular and Cellular Probes*, 21, 222–225.
26 Barrett, J.C. (2005) Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*, 21, 263–265.
27 Drysdale, C.M., McGraw, D.W., Stack, C.B. *et al.* (2000) Complex promoter and coding region b2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. *Proceedings of the National Academy of Sciences of the United States of America*, 97, 10483–10488.
28 Mohamed-Hussein, Z.A. & Harun, S. (2009) Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data. *Theoretical Biology and Medical Modelling*, 1, 6–18.
29 Jalba, M.S., Rhoads, G.G. & Demissie, K. (2008) Association of codon 16 and codon 27 beta 2-adrenergic receptor gene polymorphisms with obesity: a meta-analysis. *Obesity (Silver Spring)*, 16, 2096–2106.
30 Maxwell, T.J., Ameyaw, M.M., Pritchard, S. *et al.* (2005) Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. *International Journal of Molecular Medicine*, 16, 573–580.
31 Kurabayashi, T., Yahata, T., Quan, J. *et al.* (2006) Association of polymorphisms in the beta2 and beta3 adrenoceptor gene with polycystic ovary syndrome. *The Journal of Reproductive Medicine*, 51, 389–393.
32 Kunnas, T., Lahtio, R., Kortelainen, M.I. *et al.* (2009) Gln27Glu variant of Beta2-adrenoceptor gene affects male type fat accumulation in women. *Lipids in Health and Disease*, 8, 43.
33 Green, S.A. & Liggett, S.B. (1994) A proline-rich region of the third intracellular loop imparts phenotypic beta 1-versus beta 2-adrenergic receptor coupling and sequestration. *The Journal of Biological Chemistry*, 269, 26215–26219.
34 Large, V., Hellström, L., Reynoldsottir, S. *et al.* (1997) Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. *The Journal of Clinical Investigation*, 100, 3005–3013.
35 McGraw, D.W., Forbes, S.L., Kramer, L.A. *et al.* (1998) Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. *The Journal of Clinical Investigation*, 102, 1927–1932.